

Master program in Cancer Biology

Internship proposal form 2026

☒ **MASTER 1**

☒ **MASTER 2**

Title	Caracterization of RUVBL 1/2, a new target in colorectal cancer
Host laboratory	Regulation of Gene Expression
Name of the PI	Dominique Helmlinger
Supervisor	Bérengère PRADET-BALADE
E-mail- Contact	pradet@crbm.cnrs.fr
Description (10 lines)	We recently found that the drug CB-6644 is cytotoxic in pre-clinical models that recapitulate a very aggressive subtype of colorectal cancer. CB-6644 inhibits the ATPase activity of RUVBL 1/2, which is part of chromatin remodelers and cytoplasmic chaperones. The Master student will use new tools that we develop in collaboration with chemists, for affinity-purifications and targeted degradation (PROTAC) of RUVBL 1/2, in transcriptomics and proteomics. These experiments will provide a comprehensive understanding of RUVBL 1/2 activity in colorectal cancer, an important question both for basic and translational biology.
Duration (2 to 6 months)	6 months